Synthetic Biologics (SYN) shares were higher over 3% in recent trade after a study at Cedars-Sinai Medical Center supported its contention that methane regulating treatments can have a positive impact on Type 2 diabetes and obesity as well as constipation-predominant irritable bowel syndrome (C-IBS).
SYN is trading in the lower half of the 52-week range between $0.95 and $3.64.
The study showed that eradication of breath methane and reduction of intestinal levels of the most common methanogenic bacterium in the human gut resulted in improved insulin sensitivity by up to 50%, and a reduction in total cholesterol and LDL cholesterol levels in pre-diabetic, obese human subjects.
Synthetics Biologics’ most advanced potential treatment is SYN-010 to reduce the impact of methane producing organisms on C-IBS, with a Phase II trial expected to start during the second half of 2014.
“Cedars-Sinai researchers have previously shown that the presence of methane in the gut is associated with a slowing of intestinal transit, which may also allow for increased time for absorption of nutrients and enhanced energy harvest thus contributing to a variety of diseases including C-IBS, diabetes and obesity,” CEO Jeffrey Riley said in a statement. “The results from this new research provide further exciting insight into the role of gut methane in various metabolic diseases, including Type 2 diabetes and obesity.”